Document ID: chunk:federal_register_of_legislation:F2022C00917:front:0:p3
Version: federal_register_of_legislation:F2022C00917
Segment Type: other
Provision Reference: 
Character Range: 5753–8831

onset of psoriasis;
(2)          taking a drug from the specified list of drugs for at least the seven days before the clinical onset of psoriasis;
            Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(3)          taking a drug which is associated in the individual with:
(a)          the development of psoriasis during drug therapy; and
(b)          the improvement of psoriasis within two months of discontinuing or tapering drug therapy;
where taking the drug continued for at least the seven days before the clinical onset of psoriasis;
(4)          withdrawing from tumour necrosis factor-α inhibitor treatment in the six months before the clinical onset of psoriasis;
(5)          withdrawing from systemic glucocorticoids, moderate potency topical glucocorticoids or high potency topical glucocorticoids in the 30 days before the clinical onset of psoriasis;
Note: moderate potency topical glucocorticoids and high potency topical glucocorticoids are defined in the Schedule 1 - Dictionary.
(6)          having a Streptococcus pyogenes infection of the pharynx, tonsils or skin within the 30 days before the clinical onset of psoriasis;
(7)          having infection with human immunodeficiency virus before the clinical onset of psoriasis;
(8)          having smoked at least ten pack-years of tobacco products before the clinical onset of psoriasis;
            Note: one pack-year is defined in the Schedule 1 - Dictionary.
(9)          being exposed to second-hand smoke for at least 10,000 hours before the clinical onset of psoriasis;
            Note: being exposed to second-hand smoke is defined in the Schedule 1 - Dictionary.
(10)      being overweight or obese for at least five years before the clinical onset of psoriasis;
            Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
(11)      for impetigo herpetiformis only, being pregnant within the six weeks before the clinical onset of impetigo herpetiformis;
            Note: impetigo herpetiformis is defined in the Schedule 1 - Dictionary.
(12)      having an injury to the skin of the affected site or developing a lesion of the affected site within the 30 days before the clinical worsening of psoriasis;
(13)      taking a drug from the specified list of drugs for at least the seven days before the clinical worsening of psoriasis;
            Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(14)      taking a drug which is associated in the individual with:
(a)          the worsening of psoriasis during drug therapy; and
(b)          the improvement of psoriasis within two months of discontinuing or tapering drug therapy;
where taking the drug continued for at least the seven days before the clinical worsening of psoriasis;
(15)      withdrawing from tumour necrosis factor-α inhibitor treatment in the six months before the clinical worsening of psoriasis;
(16)      withdrawing from systemic glucocorticoids, moderate potency topical glucocorticoids or high potency topical glucocorticoids in the 30